It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
There are genetic and environmental risk factors that contribute to the development of cognitive decline in Alzheimer’s disease (AD). Some of these include the genetic predisposition of the apolipoprotein E4 genotype, consuming a high-fat diet (HFD), and the female sex. Brain insulin receptor resistance and deficiency have also been shown to be associated with AD and cognitive impairment. Intranasal (INL) insulin enhances cognition in AD, but the response varies due to genotype, diet, and sex. We investigated here the combination of these risk factors in a humanized mouse model, expressing E3 or E4, following a HFD in males and females on cognitive performance and the brain distribution of insulin following INL delivery. The HFD had a negative effect on survival in male mice only, requiring sex to be collapsed. We found many genotype, diet, and genotype x diet effects in anxiety-related tasks. We further found beneficial effects of INL insulin in our memory tests, with the most important findings showing a beneficial effect of INL insulin in mice on a HFD. We found insulin distribution throughout the brain after INL delivery was largely unaffected by diet and genotype, indicating these susceptible groups can still receive adequate levels of insulin following INL delivery. Our findings support the involvement of brain insulin signaling in cognition and highlight continuing efforts investigating mechanisms resulting from treatment with INL insulin.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Oregon Health & Science University, Department of Behavioral Neuroscience, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)
2 Veterans Affairs Puget Sound Health Care System, Geriatric Research Education and Clinical Center, Seattle, USA (GRID:grid.511190.d) (ISNI:0000 0004 7648 112X); University of Washington, Department of Medicine, Seattle, USA (GRID:grid.34477.33) (ISNI:0000 0001 2298 6657)
3 Veterans Affairs Puget Sound Health Care System, Geriatric Research Education and Clinical Center, Seattle, USA (GRID:grid.511190.d) (ISNI:0000 0004 7648 112X)
4 Oregon Health & Science University, Department of Behavioral Neuroscience, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); ONPRC, Oregon Health & Science University, Division of Neuroscience, Departments of Neurology and Radiation Medicine, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)